Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine in Major Depressive Disorder
NCT01075529Phase 4Completed
- Sponsor
- Kaohsiung Municipal Kai-Suan Psychiatric Hospital
- Start
- Mar 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluoxetine in major depressive disorder (MDD), sponsored by Kaohsiung Municipal Kai-Suan Psychiatric Hospital. Primary endpoint: Stable response (50% reduction in HAMD-17) at 6 weeks. Started Mar 2007; status: completed.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01075529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01075529.